SCHEMBL13879475

SCHEMBL13879475

O=C1NC(Cc2c[nH]c3ccccc23)C(=O)N1c1ccccc1Cl

nearest known ligand 0.62

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 5/20 0.62
MEN1 O00255 3/20 0.62
L3MBTL1 Q9Y468 2/20 0.62
ALOX5 P09917 1/20 0.61
TNF P01375 1/20 0.60
NPSR1 Q6W5P4 1/20 0.59
RIPK1 Q13546 4/20 0.56
MAPT P10636 3/20 0.56
IDO1 P14902 2/20 0.56
TP53 P04637 1/20 0.56
GLA P06280 1/20 0.56
CYP3A4 P08684 1/20 0.56
THRB P10828 1/20 0.56
SMN1; SMN2 Q16637 1/20 0.56
HSD17B10 Q99714 1/20 0.56
LMNA P02545 1/20 0.53
PKM P14618 1/20 0.53
KDM4E B2RXH2 1/20 0.51
ALDH1A1 P00352 1/20 0.51
POLB P06746 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13879424 0.83 NPSR1 (0.65) KMT2AMEN1L3MBTL1ALOX5TNF
SCHEMBL13879430 0.83 NPSR1 (0.71) KMT2AMEN1L3MBTL1ALOX5TNF
SCHEMBL13879541 0.83 NPSR1 (0.61) KMT2AMEN1L3MBTL1TNFNPSR1
SCHEMBL11639246 0.83 NPSR1 (0.73) KMT2AMEN1L3MBTL1TNFNPSR1
SCHEMBL13879470 0.81 NPSR1 (0.62) KMT2AMEN1L3MBTL1ALOX5TNF
SCHEMBL13879380 0.78 NPSR1 (0.58) KMT2AMEN1L3MBTL1TNFNPSR1
SCHEMBL14546943 0.78 NPSR1 (0.58) KMT2AMEN1L3MBTL1TNFNPSR1
SCHEMBL837717 0.77 RIPK1 (0.79) KMT2AMEN1L3MBTL1TNFNPSR1
SCHEMBL21400727 0.77 KMT2A (0.67) KMT2AMEN1L3MBTL1TNFNPSR1
SCHEMBL876699 0.77 RIPK1 (0.79) KMT2AMEN1L3MBTL1TNFNPSR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090099186-A1 INHIBITORS OF VIRAL REPLICATION INTERMUNE, INC. 2009-04-16 US disclosed
US-20090099186-A1 INHIBITORS OF VIRAL REPLICATION INTERMUNE, INC. 2009-04-16 US disclosed
WO-2007047146-A2 INHIBITORS OF VIRAL REPLICATION INTERMUNE, INC. (US) 2007-04-26 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090099186-A1 INHIBITORS OF VIRAL REPLICATION EIF2AK2, HAVCR2, RTF2 KMT2A 2463/4885MEN1 4395/4885L3MBTL1 1550/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.